Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals Stock
We can see a decrease in the price for Hikma Pharmaceuticals. Compared to yesterday it has lost -€0.200 (-1.110%).
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | -1.110% | -2.703% | 3.448% | -24.370% | 2.273% | -7.216% | -37.063% |
| Indivior plc | -1.400% | -5.298% | -3.378% | 148.696% | -4.667% | 31.494% | 400.437% |
| Viatris Inc. | -1.740% | 8.153% | 15.582% | -0.606% | 8.923% | 7.746% | -24.507% |
| Repligen Corp. | -1.150% | -0.554% | 4.319% | -7.380% | 2.023% | -12.602% | -16.063% |
Comments
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was downgraded by analysts at Barclays PLC to an "underweight" rating.
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat